Dose intensity of preparative regimens for acute myeloid leukemia - One-size-fits-all or tailor-made?

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 4, 2010, Pages 509-517

  Appelbaum, Frederick R ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Comorbidity indices; Preparative regimens; Transplantation

Indexed keywords

BECLOMETASONE; BILIRUBIN; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FLUDARABINE; PYRROLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; BACTEREMIA; CANCER MORTALITY; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MYCOSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION PNEUMONIA; RADIOIMMUNOTHERAPY; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS; WHOLE BODY RADIATION;

AGE FACTORS; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 78649920032     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.013     Document Type: Review

References (18)

1. R.A. Clift, C.D. Buckner, and F.R. Appelbaum Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens Blood 76 1990 1867 1871
2. M. de Lima, A. Anagnostopoulos, and M. Munsell Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865 872
3. E.P. Alyea, H.T. Kim, and V. Ho Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age Blood 105 2005 1810 1814
4. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
5. B. Lowenberg, G.J. Ossenkoppele, and W. van Putten High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
6. W.J. Hogan, M. Maris, and B. Storer Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients Blood 103 2004 78 84 (Pubitemid 38029921)
7. F. Weissinger, B.M. Sandmaier, and D.G. Maloney Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings Blood 98 2001 3584 3588
8. T. Fukuda, R.C. Hackman, and K.A. Guthrie Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation Blood 102 2003 2777 2785 (Pubitemid 37248846)
9. C. Junghanss, K.A. Marr, and R.A. Carter Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study Biol Blood Marrow Transplant 8 2002 512 520 (Pubitemid 35174825)
10. M. Mielcarek, P.J. Martin, and W. Leisenring Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756 762
11. T. Parimon, D.H. Au, and P.J. Martin A risk score for mortality after allogeneic hematopoietic cell transplantation Ann Intern Med 144 2006 407 414
12. M.L. Sorror, M.B. Maris, and R. Storb Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2005 2912 2919
13. M.L. Sorror, B.M. Sandmaier, and B.E. Storer Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation J Clin Oncol 25 2007 4246 4254
14. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med, in press.
15. J.M. Pagel, F.R. Appelbaum, and J.F. Eary 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission Blood 107 2006 2184 2191
16. J.M. Pagel, T.A. Gooley, and J. Rajendran Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome Blood 114 2009 5444 5453
17. J.M. Pagel, D.C. Matthews, and A. Kenoyer Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia Cancer Res 69 2009 185 192
18. D.J. Green, J.M. Pagel, and E.R. Nemecek Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates Blood 114 2009 1226 1235